FB 825

Drug Profile

FB 825

Alternative Names: Anti-CEmX monoclonal antibody - Fountain Biopharma; FB-825; h4B12

Latest Information Update: 18 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Academia Sinica
  • Developer Fountain BioPharma
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; IgE receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Allergic asthma; Allergic rhinitis; Atopic dermatitis

Most Recent Events

  • 01 Feb 2016 Fountain BioPharma completes a phase I trial in Atopic dermatitis, allergic asthma and allergic rhinitis (In volunteers) in USA (NCT02309762)
  • 25 Jul 2015 Fountain BioPharma has patent protection for FB 825 in Singapore, Korea, South Africa, USA, Australia, Indonesia and Russia
  • 07 Apr 2015 Fountain BioPharma has patent protection for FB 825 in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top